Literature DB >> 22903167

State of the art diagnostic of mold diseases: a practical guide for clinicians.

F Beirão1, R Araujo.   

Abstract

The epidemiology of fungal diseases changed, and molds have been increasingly associated with high mortality in severe immunocompromised patients. Invasive mold diseases may originate from the airborne conidia through inhalation or inoculation in skin fissures associated with indwelling catheters, wounds, burns, or onychomycosis. The diagnosis and treatment of fungal diseases is problematic and raises considerable challenges. Diagnosis of invasive mold diseases includes several methodologies, of which the most commonly used are the cultural methods, antigen testing, nucleic acid detection, and radiological imaging. Galactomannan and (1 → 3)-β-D-glucan detection significantly improved mold diagnosis in the last decade. Several molecular strategies have been proposed over the years but no consensus was achieved for standardized protocols or cut-off values. Recently, the first commercially available molecular assay for detection of Aspergillus was tested and the results were highly reproducible. In addition, blood cultures may also be helpful for invasive aspergillosis by following a novel procedure for the recovery of Aspergillus spp. from blood cultures. The association of distinct diagnostic methods, particularly molecular tests, galactomannan, and/or (1 → 3)-β-D-glucan detection, may provide earlier and more sensitive diagnosis of mold diseases and be indicative for early antifungal treatment. Accurate routine use of diagnostic tests can be cost-effective for laboratories and be of great value to patients.

Entities:  

Mesh:

Year:  2012        PMID: 22903167     DOI: 10.1007/s10096-012-1722-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  61 in total

1.  Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens.

Authors:  Claudia Schabereiter-Gurtner; Brigitte Selitsch; Manfred L Rotter; Alexander M Hirschl; Birgit Willinger
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

Review 2.  [Aspergillosis in pulmonary transplantation].

Authors:  A de Pablo; P Ussetti; M Cruz Carreño; T Lázaro; M J Ferreiro; A López; P Mendaza; J Estada
Journal:  Enferm Infecc Microbiol Clin       Date:  2000-05       Impact factor: 1.731

Review 3.  Benefit of CT scanning for assessing pulmonary disease in the immunodepressed patient.

Authors:  C Godet; A Elsendoorn; F Roblot
Journal:  Diagn Interv Imaging       Date:  2012-05-26       Impact factor: 4.026

4.  Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies.

Authors:  Me-Linh Luong; Charles Filion; Annie-Claude Labbé; Jean Roy; Jacques Pépin; Julia Cadrin-Tourigny; Stéphane Carignan; Donald C Sheppard; Michel Laverdière
Journal:  Diagn Microbiol Infect Dis       Date:  2010-10       Impact factor: 2.803

Review 5.  Diagnosis of histoplasmosis in immunosuppressed patients.

Authors:  Carol A Kauffman
Journal:  Curr Opin Infect Dis       Date:  2008-08       Impact factor: 4.915

6.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

7.  False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients.

Authors:  Jesus Fortún; Pilar Martín-Dávila; Maria E Alvarez; Francesca Norman; Aurora Sánchez-Sousa; Luis Gajate; Rafael Bárcena; S Javier Nuño; Santiago Moreno
Journal:  Transplantation       Date:  2009-01-27       Impact factor: 4.939

Review 8.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

9.  Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients.

Authors:  R Y Hachem; D P Kontoyiannis; R F Chemaly; Y Jiang; R Reitzel; I Raad
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

Review 10.  Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens.

Authors:  A Kedzierska; P Kochan; A Pietrzyk; J Kedzierska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 5.103

View more
  3 in total

1.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

2.  [Lung transplantation].

Authors:  U Sommerwerck; T Rabis; P Fleimisch; H Carstens; H Teschler; M Kamler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

Review 3.  Histopathological implications of Aspergillus infection in lung.

Authors:  Naobumi Tochigi; Yoichiro Okubo; Tsunehiro Ando; Megumi Wakayama; Minoru Shinozaki; Kyoko Gocho; Yoshinobu Hata; Takao Ishiwatari; Tetsuo Nemoto; Kazutoshi Shibuya
Journal:  Mediators Inflamm       Date:  2013-11-20       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.